Sol-Gel Technologies Ltd. (SLGL)

Market Cap	22.54M
Revenue (ttm)	12.10M
Net Income (ttm)	-13.04M
Shares Out	2.79M
EPS (ttm)	-4.68
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,552
Open	8.19
Previous Close	8.11
Day's Range	7.90 - 8.19
52-Week Range	3.34 - 16.50
Beta	1.10
Analysts	Buy
Price Target	40.00 (+394.44%)
Earnings Date	Aug 15, 2025

About SLGL

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has com...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 23, 2018
• Employees: 34
• Stock Exchange: NASDAQ
• Ticker Symbol: SLGL
• Website: https://www.sol-gel.com

Financial Performance

In 2024, Sol-Gel Technologies's revenue was $11.54 million, an increase of 642.47% compared to the previous year's $1.55 million. Losses were -$10.58 million, -61.16% less than in 2023.

Analyst Summary

According to one analyst, the rating for SLGL stock is "Buy" and the 12-month stock price target is $40.0.

Price Target

$40.0

(394.44% upside)

Analyst Consensus: Buy